The effects of early postoperative immunization with xenogeneic embryo proteins on Lewis lung carcinoma model
Keywords:
chicken embryo proteins, Lewis lung carcinoma, xenogeneic anticancer vaccineAbstract
Summary. Aim: To investigate the effect of chicken embryo proteins (CEP) as a prototype of xenogeneic vaccine on immune reactions in mice immunized after Lewis lung carcinoma (LLC) surgical removal. Materials and Methods: C57Bl male mice were immunized on days 1, 8, and 15 after surgical removal of LLC. The immune response was assessed on days 7, 14, 21 and 28 after tumor resection. Cytotoxic activity of natural killer cells (NK) and cytotoxic T-lymphocytes as well as antibody dependent cellular cytotoxicity was estimated in MTT-assay; specific antibodies were detected in ELISA; lymphocyte proliferation was tested in reaction of in vitro blast transformation. Results: None of the immunized mice developed LLC metastases. Immunization with CEP seems to prevent the potential decrease in NK cell cytotoxic activity and spontaneous blast transformation activity of lymphocytes following the surgically induced stress. Further research on improving immunization schedule and elucidating the mechanisms of NK modulation with CEP is needed.
References
Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 2015; 75: 5–10.
Tagliamonte M, Petrizzo A, Tornesello ML, et al. Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014; 10: 3332–46.
Cavallo F, Aurisicchio L, Mancini R, Ciliberto G. Xenogene vaccination in the therapy of cancer. Expert Opin Biol Ther 2014; 14: 1427–42.
Aurisicchio L, Roscilli G, Marra E, et al. Superior immunologic and therapeutic efficacy of a xenogeneic genetic cancer vaccine targeting carcinoembryonic human antigen. Hum Gene Ther 2015; 26: 386–98.
Luo Y, Wen Y-J, Ding Zh-Y, et al. Іmmunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin Cancer Res 2006; 12: 1813–9.
Su JM, Wei YQ, Tian L, et al. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 2003; 63: 600–7.
Zhang W, Liu J, Wu Y, et al. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous a fetoprotein in mice. Biochem Biophys Res Commun 2008; 376: 10–4.
He QM, Wei YQ, Tian L, et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003; 278: 21831–6.
Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001; 167: 7150–6.
Ginsberg BA, Gallardo HF, Rasalan TS, et al. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res 2010; 16: 4057–65.
Yuan J, Ku GY, Gallardo HF, et al. Wolchok, Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009; 9: 5.
Jiao JG, Li YN, Wang H, et al. A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig Liver Dis 2006; 38: 578–87.
Tan GH, Wei YQ, Tian L, et al. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol 2004; 34: 2012–21.
Liu JY, Wei YQ, Yang L, et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003; 102: 1815–23.
Yu WY, Chuang TF, Guichard C, et al. Chicken HSP70 DNA vaccine inhibits tumor growth in a canine cancer model. Vaccine 2011; 29: 3489–500.
Denies S, Cicchelero L, Polis I, Sanders NN. Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs. Oncotarget 2016; 7: 10905–16.
Denies S, Leyman B, Huysmans H, et al. Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice. Cancer Immunol Immunother 2017; 66: 1545–55.
Wei YQ, Wang QR, Zhao X, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160–6.
Alexander AN, Huelsmeyer MK, Mitzey A, et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 2006; 55: 433–42.
Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 1284–90.
Riccardo F, Iussich S, Maniscalco L, et al. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res 2014; 15: 3753–62.
Sarbu L, Kitchell BE, Bergman PJ. Safety of administering the canine melanoma DNA vaccine (Oncept) to cats with malignant melanoma — a retrospective study. J Feline Med Surg 2017; 19: 224–30.
Seledtsova GV, Shishkov AA, Kaschenko EA, et al. Xenogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefits. Eur J Dermatol 2016; 26: 138–43.
Seledtsova GV, Shishkov AA, Kaschenko EA, Seledtsov VI. Xenogeneic cell-based vaccine therapy for colorectal cancer: Safety, association of clinical effects with vaccine-induced immune responses. Biomed Pharmacother 2016; 83: 1247–52.
Yuan J, Ku GY, Adamow M, et al. Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. J Immunother Cancer 2013; 1: 2.
Verganti S, Berlato D, Blackwood L, et al. Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK. J Small Anim Pract 2017; 58: 10–6.
Symchych TV, Fedosova NI, Karaman OM, et al. Anticancer effectiveness of vaccination based on xenogeneic embryo proteins applied in different schedules. Exp Oncol 2015; 37: 197–202.
Symchych TV, Fedosova NI, Karaman OM, et al. Anticancer effect and immunologic response to xenogeneic embryonic proteins in mice bearing Ehrlich solid carcinoma. Exp Oncol 2017; 39: 42–8.
Kozhemyakin YM, Khromov OS, Filonenko MA, Sayfutdinova HA. Guideline on Management of Laboratory Animals and Work with Them. Kyiv: Avitsena, 2002. 179 p. (in Ukrainian).
Isokawa K, Rezaee M, Wunsch A, et al. Identification of transferrin as one of multiple EDTA-extractable extracellular proteins involved in early chick heart morphogenesis. J Cell Biochem 1994; 54: 207–18.
van de Loosdrecht AA, Beelen RHJ, Ossenkoppele GJ, et al. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Met 1994; 174: 311–20.
Autenshlius AI, Ivanova OV, Gauzer VV, Cemernikov VA. Antibody to Bacillus megaterium H. glycoprotein in pregnant women with a pathological course of pregnancy. Bull Exp Biol Med 1995; 120: 203–6 (in Russian).
Egorov AM, Osipov AP, Dzantiev BB, Gavrilova EM. Theory and Practice of Immunoassay. Moscow: Higher School, 1991. 288 p. (in Russian)
Widmann FK. Clinical Interpretation of Laboratory Tests. Edition 9. Philadelphia: F.A. Davis Co, 1983. 179 p.
Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol 2015; 12: 213–26.
Marik PE, Flmmer M. The immune response to surgery and trauma: Implications for treatment. J Trauma Acute Care Surg 2012; 73: 801–8.
Tai L-H, de Souza CT, Bélanger S, et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res 2013; 73: 97–107.
Tai L-H, Auer R. Attacking postoperative metastases using perioperative oncolytic viruses and viral vaccines. Front Oncol 2014; 4: 217.
Fogel M, Gorelik E, Segal S, Feldmn M. Differences in cell surface antigens of tumor metastases and those of the local tumor. J Natl Cancer Inst 1979; 62: 585–8.
Brune IB, Wilke W, Hensle T, et al. Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 1999; 177: 55–60.
Hirai T, Matsumoto H, Yamashita K, et al. Surgical oncotaxis — excessive surgical stress and postoperative complications contribute to enhancing tumor metastasis, resulting in a poor prognosis for cancer patients. Ann Thorac Cardiovasc Surg 2005; 11: 4–6.
Neeman E, Ben-Eliyahu S. The perioperative period and promotion of cancer metastasis: New outlooks on mediating mechanisms and immune involvement. Brain Behav Immun 2013; 30 Supl: S32–S40.
Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol 2015; 12: 213–26.
Tai L-H, Zhang J, Scott KJ, et al. Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. Clin Cancer Res 2013; 18: 5104–15.
Goldfarb Y, Sorski L, Benish M, et al. Improving postoperative immune status and resistance to cancer metastasis. A combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg 2011; 253: 798–810.
Park CG, Hartl CA, Schmid D, et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci Transl Med 2018 10: pii: eaar1916.
Carter JJ, Feingold DL, Wildbrett P, et al. Significant reduction of laparotomy-associated lung metastases and subcutaneous tumors after perioperative immunomodulation with flt3 ligand in mice. Surg Innov 2005; 12: 319–25.
Carter JJ, Feingold DL, Oh A, et al. Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice. Surg Innov 2006; 13: 41–7.
Colacchio TA, Yeager MP, Hildebrandt LW. Perioperative immunomodulation in cancer surgery. Am J Surg 1994; 167: 174–9.
Tjota A, Zhang YQ, Piedmonte MR, Lee CL. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor. J Urol 1991; 146: 177–83.
Ananth AA, Tai LH, Lansdell C, et al. Surgical stress abrogates pre-existing protective T cell mediated anti-tumor immunity leading to postoperative cancer recurrence. PLoS One 2016; 11: e0155947.
Yamaguchi Y, Hihara J, Hironaka K, et al. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome. Oncol Rep 2006; 15: 895–901.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
